Green Table Global recently held an event in Southampton NY bringing together cannabis companies and cannabis investors. It was a beautiful evening and even though it was a Sunday night, there was plenty of interest. Investors listened to presentations from Matt Karnes of GreenWave Advisors, Multiverse Capital, Green Revolution, Franki Global, and Kannalife.
Multiverse Capital is a Venture Capital Firm Investing in all Sectors of the Global Cannabis Industry. The Multiverse name is reflective of our broad-based strategy since it invests in both private and public cannabis companies, globally. Multiverse Capital has 3 distinct cannabis investment venture funds: medicinal, adult use (recreational), and ancillary (real estate, ancillary products & services, and biotech). Multiverse Capital management and advisors have worked with hundreds of private and public cannabis companies in over 15 countries and have a combined 16 years of commercial cannabis and industrial hemp experience.
Green Revolution is the first crossover cannabis health and lifestyle brand in the country. At Green Revolution, the company has created a family of cannabis-based products for all vital dimensions of your life. By using the latest scientific methods and innovative technologies, Green Revolution has become a recognized leader in multiple product categories within the cannabis industry and is poised for national expansion. Its products serve a broad demographic from 21 to 80 and have consistently proven to be the go to option for veteran users as well as people experiencing cannabis for the very first time.
Franki Global Inc. is a unique video-based social media experience via its brand “franki”. franki connects consumers and businesses through an authentic social video review experience. Unlike other review apps, franki invites consumers to create video reviews that share their true opinion and allowing franki users to discover their next adventure – all whilst giving businesses and brands valuable feedback on their products and services.
Kannalife Sciences, based at the Pennsylvania Biotechnology Center is a pharmaceutical and phyto-medical company involved in the research and development of novel therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife holds an exclusive license with NIH for the commercialization of US Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants” to treat Hepatic Encephalopathy (HE) and an additional license to treat Chronic Traumatic Encephalopathy (CTE).